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Abstract
Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by
modifying the chemical structure of thalidomide to improve its potency and reduce its side effects.
Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects
of sedation and neuropathy and has emerged as a drug with activity against various hematological
and solid malignancies. It is approved by FDA for clinical use in myelodysplastic syndromes with
deletion of chromosome 5q and multiple myeloma. Lenalidomide has been shown to be an
immunomodulator, affecting both cellular and humoral limbs of the immune system. It has also been
shown to have anti-angiogenic properties. Newer studies demonstrate its effects on signal
transduction that can partly explain its selective efficacy in subsets of MDS. Even though the exact
molecular targets of lenalidomide are not well known, its activity across a spectrum of neoplastic
conditions highlights the possibility of multiple target sites of action.
Thalidomide is the first immunomodulatory 
drug with multiple effects on the immune 
system
Immunomodulatory drugs (IMiDs) CC-5013 (Revlimid
TM, Lenalidomide) and CC-4047 (ActimidTM, Pomalid-
omide) are a series of synthetic compounds derived using
structural modifications of the chemical structure of tha-
lidomide. Thalidomide (a-(N-phthalimido) glutaramide)
was synthesized in Germany, in 1954, from glutamic acid,
to be used as a sedative and hypnotic anti-emetic drug,
indicated to treat morning sickness in the first trimester of
gestation. Thalidomide was banned in the 1960s because
of the reports of congenital malformations like phocome-
lia associated with its use in pregnant women. One of the
possible hypothesis to explain this teratogenecity is that
thalidomide creates oxidative stress by with subsequent
downregulation of Wnt and Akt survival pathways which
induces apoptosis during early embryonic limb develop-
ment resulting in limb truncations[1]. Following an
observation in 1965 that thalidomide administration
improved the inflammatory lesions of erythema nodo-
sum leprosum (ENL) in a patient suffering from sleep dif-
ficulty, the use of thalidomide continued. Eventually in
1998, FDA approved the drug for the treatment of ENL,
with tight restrictions on its marketing. ENL is an immune
complex mediated inflammatory reaction that occurs dur-
ing therapy in lepromatous leprosy patients. It is com-
monly associated with systemic symptoms, and
constitutes a medical emergency with urgent need of ther-
apy with anti-inflammatory/immunomodulatory drugs
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to prevent long term disabilities. Research into the mech-
anism of action of thalidomide unraveled an immunolog-
ical and immunomodulatory basis for the effect, notably
inhibition of denovo IgM antibody synthesis[2] by possi-
bly affecting the macrophages, B-cells, helper or suppres-
sor lymphocytes, decreasing TNF-α synthesis and
modulating the T cell subsets by increasing the T-helper
population after therapy[3]. TNF-α is a potent pro inflam-
matory cytokine, and is also involved in the pathogenesis
of neural damage in leprosy. The inhibitory effect of tha-
lidomide on TNF-α is a consequence of increased degra-
dation of its mRNA due to the drug [4]. Thalidomide also
regulates the levels of IL-6 and IFN-γ in ENL patients, fur-
ther contributing to the immunomodulatory mechanism
of action. Interest in thalidomide as a neoplastic agent
intensified after the demonstration of antiangiogenic
activity in animal models. The recognition that angiogen-
esis plays an important pathogenic role in multiple mye-
loma as reflected by increased bone marrow
microvascular density and VEGF (vascular endothelial
growth factor) levels, prompted the clinical use of thalid-
omide in relapsed/refractory multiple myeloma. With the
recognition of adverse effects like neuropathy, deep vein
thrombosis, and sedation, more potent and safer ana-
logues were developed by Celgene. Lenalidomide is one
such analogue which has been extensively tested and
proven to be more potent than thalidomide and has fewer
adverse effects compared to thalidomide. Another newer
thalidomide analogue is pomalidomide. Figure 1 consists
of the chemical structures and names of these three com-
pounds and Table 1 illustrates the differences amongst
them.
Mechanism of action of Lenalidomide
The clinical evidence for therapeutic potential of lenalid-
omide in various malignant conditions is consistent with
the multitude of pharmacodynamic effects that have been
shown in vitro and in animal models. Studies have shown
that lenalidomide may work through various mechanisms
in different hematologic malignancies. These mechanism
involved direct cytotoxicity as well as through indirect
effects on tumor immunity. Thus the differential efficacy
noted with lenalidomide therapy among various disease
states can possibly be explained individual's immune sta-
tus and disease specific pathophysiology. Following are
the different mechanisms explained by which lenalido-
mide acts in the body.
Immunomodulation
The immune system is comprised of cellular (macro-
phages, dendritic cells, NK cells, T cells and B cells), and
humoral components (antibodies, cytokines). The
immune system can prevent development of cancers by
eliminating or suppressing oncogenic viral infections,
altering the inflammatory milieu conducive to tumor gen-
esis, and by immune surveillance by identifying and
destroying transformed cells before they can cause
harm[5].
Lenalidomide has been shown to modulate different
components of the immune system by altering cytokine
production, regulating T cell co stimulation and augment-
ing the NK cell cytotoxicity. Immunomodulatory proper-
ties of Lenalidomide are implicated in its clinical efficacy
in multiple myeloma, CLL and myelodysplastic syn-
dromes; where the disease pathogenesis involves in part a
deregulated immune system in the form of altered
cytokine networks in tumor microenvironment, defective
Table 1: Differences between thalidomide, lenalidomide and pomalidomide
Name Thalidomide Lenalidomide Pomalidomide
Empirical Formula C13H10N2O4 C13H13N3O3 C13H11N3O4
Molecular weight 258.2 259.3 273.2
Chemical Structural Thalidomide has two oxo groups 
in Phthaloyl ring
Lenalidomide has amino group at 
4th position and single oxo group 
in Phthaloyl ring
Pomalidomide has amino group at 
4th position and two oxo groups in 
Phthaloyl ring
Effects on T-cell proliferation Thalidomide stimulates T cell 
proliferation and increases IFN-γ 
and IL-2 production
Lenalidomide is 100–1000 times 
more potent in stimulating T cell 
proliferation and IFN-γ and IL-2 
production than thalidomide
Pomalidomide is similar to 
lenalidomide, in addition, it also 
enhances transcription factor T-
bet, which reverts Th2 cells into 
Th1 like effector cells in vitro
Adverse Effects Thalidomide has higher incidence 
of side effects like sedation, 
neuropathy and constipation.
Lenalidomide has lower incidence 
of adverse effects namely sedation, 
constipation and neuropathy than 
thalidomide.
Pomalidomide has lower incidence 
of adverse effects like sedation, 
constipation and neuropathy than 
thalidomide.
Teratogenecity Thalidomide is a known teratogen. Lenalidomide is not teratogenic in 
rabbit models
Pomalidomide is a known 
teratogen.Journal of Hematology & Oncology 2009, 2:36 http://www.jhoonline.org/content/2/1/36
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T cell regulation of host-tumor immune interactions, and
diminished NK cell activity.
Altering cytokine production
Cytokines are soluble proteins secreted by hematopoietic
and non hematopoietic cell types and are critical for both
innate and adaptive immune responses. The expression of
cytokines by cells may be altered in immunological,
inflammatory, infectious and neoplastic disease states.
Cytokines in turn exert their effects by influencing gene
activation, growth, differentiation, functional cell surface
molecule expression and cellular effector function. A
coordinated cellular and humoral (cytokines, antibodies)
interactions facilitate tumor destruction.
Lenalidomide has been shown to inhibit production of
pro inflammatory cytokines TNF-α, IL-1, IL-6, IL-12 and
elevate the production of anti-inflammatory cytokine IL-
10 from human PBMCs[6]. The downregulation of TNF-α
secretion is particularly striking and is up to 50,000 times
more when compared to thalidomide[7]. TNF-α is a
highly pleiotropic cytokine produced primarily by mono-
cytes and macrophages and plays an important role in
protective immune responses against bacterial and viral
infections. Elevated TNF-α production is implicated in the
pathogenesis of various hematologic malignancies and
may be partly responsible for stem cell apoptosis and inef-
fective hematopoiesis seen in MDS [8]. TNF-α levels in
CLL patients are also elevated and exhibit a significant
decrease as early as 7 days after lenalidomide treatment.
These reductions correlate with cytoreduction suggesting a
casual relationship with tumor growth [9].
Similarly, reduction in IL-6 and TNF-α levels could
explain the action of lenalidomide in multiple myeloma.
IL-6 inhibits the apoptosis of malignant myeloma cells
and helps in their proliferation[10]. Lenalidomide down-
regulates the production of IL-6 directly and also by inhib-
iting multiple myeloma (MM) cells and bone marrow
stromal cells (BMSC) interaction [11,12], which aug-
ments the apoptosis of myeloma cells[13]. The precise
mechanism of TNF-α downregulation by lenalidomide is
not known, however thalidomide has been shown to
increase the degradation of TNF-α mRNA [4,14]. It is pos-
sible that lenalidomide may work through similar mech-
anisms.
T cell activation
T cells are important effectors of immune response and
their activation is tightly regulated to prevent auto reactiv-
ity. T cell activation involves the presentation of the pep-
tide fragments displayed by antigen presenting cells
(APCs) to the T cell receptor (TCR) and it is this interac-
tion that gives specificity to the response. However this
interaction alone is not sufficient if a T cell has to generate
an effective response against the antigen. A secondary
interaction of B7 molecule on APC and CD28 on the T cell
surface provides the co stimulatory signal that augments
the T cell response and aids in T cell proliferation, differ-
entiation, and survival followed by a cascade of cytokine
and cellular responses[15].(Figure 2). IMiDs, including
lenalidomide act on T cells via B7-CD28 co stimulatory
pathway. Blockade of this interaction using the CTLA-4-Ig,
B7 blocking antibody, is partially overcome by IMiDs.
IMiDs do not up regulate expression of CD28 and B7 on
T cells and APCs respectively but they can directly induce
tyrosine phosphorylation of CD28 on T cells leading to
activation of downstream targets such as PI3K, GRB-2-OS,
and NF-κb. This might explain their ability to partially
overcome CTLA4 Ig blockade[16]. T cell co-stimulation by
lenalidomide leads to an increased Th1 type cytokine
response resulting in increased secretion of IFN-γ and IL-2
that in turn stimulate clonal T cell proliferation and NK
cell activity[6,17].
IMiDs have been shown to stimulate both cytotoxic CD8+
as well as helper CD4+ cells[18]. Their effects on T helper
cells can potentially mediate Th1 type antitumor immu-
nity in response to tumor cell vaccination in animal mod-
els[17]. The IMiD, CC-4047 (pomalidomide) enhanced
partially protective antitumor effect of whole tumor cell
vaccination in mice and generated long term immunity
against subsequent live tumor challenge[17]. In vivo pro-
Chemical structures of thalidomide, lenalidomide and pomal- idomide Figure 1
Chemical structures of thalidomide, lenalidomide 
and pomalidomide.Journal of Hematology & Oncology 2009, 2:36 http://www.jhoonline.org/content/2/1/36
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duction of IFN-γ correlated with the tumor protection.
When nude mice lacking T cells were exposed to IMiD and
tumor cells during the priming phase, they did not dem-
onstrate protection from the tumor, demonstrating that T
cells are needed for tumor immunity. The IMiD drug itself
was shown to have no direct anti tumor effect on growth
inhibition or expression of co stimulatory molecules, rul-
ing out direct cytotoxic effects. These effects can also partly
explain the beneficial effects of lenalidomide in MDS.
Clonal expansion of abnormal hematopoietic suppressive
T cells are believed to have a pathogenic role in ineffective
erythropoiesis of patients with MDS and 50% of the
patients with MDS were shown to have clonal T cells com-
pared to 5% in age matched controls[19]. It is possible
that lenalidomide may affect certain T cell subsets and
result in hematologic improvements in MDS patients.
Augmentation of NK cell function
Natural Killer (NK) Cells comprise 2% of the circulating
lymphocytes and are an important component of innate
immunity. NK cells are not driven by specificity to anti-
gens unlike T cells or B cells and are able to respond rap-
idly on contact with the target cell (cancer, viral infected)
and kill the cell with antibody dependent cell mediated
cytotoxicity(ADCC) and natural cytotoxicity. Natural
killer cells also contribute to immunoregulation by secret-
T cell activation Figure 2
T cell activation. B7-CD28 co-stimulation pathway is needed for T cell activation and CTLA4 Ig blocks this pathway leading 
to T cell inactivation. Lenalidomide acts by directly inducing tyrosine phosphorylation of CD28 on T cells leading to activation 
of downstream targets such as PI3K, GRB-2-OS, and NF-κb, thus partially overcoming CTLA4 Ig blockade and leading to T cell 
clonal proliferation.Journal of Hematology & Oncology 2009, 2:36 http://www.jhoonline.org/content/2/1/36
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ing cytokines like IFN-γ and TNF-α. Modulation of NK cell
function is also believed to contribute to the anti tumor
activity of Lenalidomide in MDS, MM and CLL.
Davies et al examined the potential immunomodulatory
effects of thalidomide and its analogues in patients with
multiple myeloma. The in vitro/in vivo role of NK cell
cytotoxicity of MM cells in thalidomide treated patient
was supported by the observation that the cell killing was
not MHC restricted and CD56(NK cell) depletion in vitro
inhibited killing of drug treated multiple myeloma
cells[20]. Furthermore, treatment with Thalidomide was
also accompanied by increased NK cell numbers and IL-2
levels. The precise mechanism whereby IMIDS increase
the NK cell number or augment its cytotoxicity is not well
known and it is possible that these effects may be indirect.
Hayashi et al in their study of IMiDs in MM cell lines have
demonstrated that when culturing PBMC with IMiDs
leads to 1.2–1.3 fold increase in the percentage of CD56
cells. IMiDs enhanced ADCC when 51 Cr-labelled MM
cells that express CD40 were incubated with rhuCD40
and then subsequently treated with PBMC cells incubated
in the presence of IMiDs for 5 days. The increase in NK cell
function may be related to the increase in IL-2 production
by the T cells as the presence of a monoclonal Ab against
IL-2 R blocked the NK cell cytotoxicity. IMiDs also were
shown not to directly activate the NK cells, as evidenced
by lack of phosphorylation of signaling molecules (ERK/
p38MAPK/Akt/PKC) in NK cells[21].
Lenalidomide also enhanced the NK cell mediated ADCC
in a series of functional in vitro studies using Rituximab
coated NHL cell lines, Trastuzumab coated breast cancer
cells expressing Her2 and cetuximab coated colon cancer
cells positive for EGFR expression. The cell killing was
increased in a dose dependent manner and presence of IL-
2 was required to achieve cell killing[22]. In another study
[23], IFN-γ production by NK cell in rituximab coated
NHL cell lines pretreated with lenalidomide, was induced
with the interaction of Ig G with FC-γ receptors in the pres-
ence of IL-2 or IL-12. Thus, lenalidomide enhanced Fc-γ
receptor signaling may also play a role in increasing the
potency of NK cells.
Anti-angiogenesis activity
The growth of the primary and metastatic tumors requires
the development of new blood vessels, a process
described as angiogenesis. Tumors possess the ability to
promote the formation of new blood vessels from preex-
isting host capillaries at a critical phase of the tumor
development when the balance of pro- angiogenic and
anti-angiogenic factors is altered. Vascular endothelial
growth factor (VEGF) and its receptors are required for the
formation of blood vessels during embryonic develop-
ment, wound healing, and carcinogenesis. Tumors are
more dependent on the VEGF-Receptor signaling for
growth and survival compared to normal endothelial cells
[24]. Early studies showed that Thalidomide had anti ang-
iogenic activity in a rabbit model of corneal neovasculari-
zation that was induced as a response to bFGF[25]. This
report led to its use in Multiple Myeloma, where it dem-
onstrated clinical benefit and was approved for use by the
FDA. Thalidomide and the newer IMiDs have also been
shown to significantly decrease the expression of ang-
iogenic factors VEGF and Interleukin-6 (IL-6) in multiple
myeloma; thereby reducing angiogenesis and hence con-
tributing to clinical activity in multiple myeloma[26]. The
newer IMiDs were found to be 2–3 times more potent
compared to thalidomide in antiangiogenic activity in
various vivo assays [27] The antiangiogenic activity of
both thalidomide and IMiDs has also been shown to be
independent of immunomodulatory effects[28].
VEGF receptors are overexpressed on blast cells in dysplas-
tic marrows in MDS patients [29]. Increased plasma levels
of VEGF R have also been correlated with lower remission
rate in patients with myelodysplastic syndromes. A recent
study in 35 MDS patients with del 5 q showed a marked
decrease in bone marrow vascularity subsequent to lenal-
idomide therapy. This reduction in vascularity correlated
with clinical responses. However VEGF levels and VEGFR
levels did not change significantly even though vasculari-
zation was decreased, supporting the notion that lenalid-
omide may uncouple angiogenesis from the effect of
VEGF[30]. Apart from alteration in the levels of VEGF,
analysis of signal transduction events show that lenalido-
mide partially inhibits Akt phosphorylation after VEGF
stimulation in endothelial cells and also has inhibitory
effects on phosphorylation of Gab1, a protein upstream of
Akt 1[31,32]. These observations demonstrate that IMiDs
may affect angiogenesis by multiple mechanisms.
Direct anti tumor activity
Lenalidomide treatment has also shown anti proliferative
activity against MDS and MM cells in the absence of
immune effector cells[33]. Malignant plasma cells derived
from refractory cases of myeloma were shown to be sus-
ceptible to IMiD induced growth arrest. Lenalidomide has
also been shown to inhibit proliferation in Burkitt's Lym-
phoma cell lines by causing dose dependant cell cycle
arrest in G0-G1 phase[34]. Lenalidomide upregulated
Cyclin dependant kinase (CDK) Inhibitor, p21 waf-1, a
key cell cycle regulator that modulates the activity of
CDKs. Similar reductions in CDK2 activity have been
demonstrated in myeloma derived cell lines, U266 and
LP-1[34]. In contrast, the normal B cells obtained from
healthy donors were immune from growth inhibition and
did not show any upregulation of p21 expression after 3
days of lenalidomide treatment. In other studies, thalido-
mide and its analogues have also been shown to induceJournal of Hematology & Oncology 2009, 2:36 http://www.jhoonline.org/content/2/1/36
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apoptosis in MM cell lines[35]. Effects on apoptosis in
MM cells is secondary to increased potentiation of TNF
related Apoptosis inducing ligand (TRAIL), inhibition of
apoptosis protein-2, increased sensitivity to Fas mediated
cell death, and up regulation of caspase-8 activation,
down regulation of caspase-8 inhibitors (FLIP, cIAP2),
down regulation of NF-κb activity and inhibition of pro-
survival effects of IGF-1[36]. The proapoptotic activity of
IMiDs has also been demonstrated in CLL. Lenalidomide
was shown to induce apoptosis and affect the Phosphoti-
dylinositol pathway in CLL cells by decreasing activation
of pro-survival kinases, erk1/2 and Akt2[37].
Interestingly, lenalidomide has shown opposite effects on
the growth of normal progenitors. When cord derived
CD34+ progenitors cells were cultured in expansion
medium supplemented with lenalidomide, there was a
dose dependent increase in the total number of CD34
cells after 6 days of culture [34]. p21 was upregulated in
normal Cd34 cells, but did not affect the CDK2 activity in
contrast to Nawalma cells (Burkitt's lymphoma cells).
While the transfusion independence seen with lenalido-
mide use in MDS can be explained by the normal progen-
itor expansion, the dose dependent cytopenias that are
common with early treatment cycles of lenalidomide may
be a result of inhibition of proliferation of abnormal
clonal cell populations in the marrow.
Effects on multiple myeloma microenvironment
Lenalidomide exerts its distinct anti myeloma effects by
altering the myeloma microenvironment. In multiple
myeloma, osteoclasts lead to bone resorption and secrete
survival factors for MM cells. The interaction between MM
cells and BMSC in turn leads to increased production of
IL-6 and other growth factors for MM cells and osteo-
clasts[38]. Lenalidomide directly decreases the formation
of tartrate- resistant acid phosphatase(TRAP)- positive
cells which form osteoclasts [11]. Additionally, it
decreases  αVβ3-integrin levels, an adhesion molecule
needed for osteoclast activation and downregulates cathe-
psin K, a major cysteine protease expressed in osteoclasts,
pertinent for matrix degradation in the resorption proc-
ess[11]. It downregulates the important mediators of oste-
oclastogenesis such as transcription factor PU.1 and MAP
kinase pERK and reduces the levels of bone remodeling
factor -receptor activator of nuclear factor-kappaB ligand.
Immunomodulators are also known to decrease the cell
surface adhesion molecules such as ICAM-1, VCAM-1 and
E -selectin [12] and inhibit the adhesion of MM cells to
BMSC. Thus, lenalidomide interferes with the synergism
amongst the osteoclasts, MM cells and BMSC and
decreases osteoclastogenesis by acting at various levels.
Selective efficacy in cells with deletion of 
chromosome 5q
The del 5q syndrome is now recognized as a distinct path-
ologic subtype of MDS with markedly better clinical
responses with lenalidomide treatment compared to non
del 5q MDS patients. The exact mechanism of action of
lenalidomide on del 5q clones is not known, but there
appears to be several candidate genes (tumor suppressor)
whose expression may be modulated by lenalidomide
treatment. Hellstrom et al [39] studied the effect of lenal-
idomide on isolated differentiating erythroblasts from del
5q MDS patients and healthy controls. The addition of
lenalidomide significantly inhibited the invitro prolifera-
tion of erythroblasts harboring del 5q while the prolifera-
tion of cells from normal controls and cells without 5q
deletion was not affected. Gene expression profiling was
performed at day 7 when a median of 97% cells in culture
from MDS patients with del5q still possess del 5q, and
thus any difference in gene expression deemed to be
reflective of del 5q cells. There was altered gene expression
in many genes, but a set of 4 genes was consistently upreg-
ulated (VSIG4, PPIC, TPBG and SPARC) by more than 2
fold in all samples. The upregulation of SPARC (Secreted
Protein Acidic and Rich in Cysteine) after treatment with
lenalidomide is particularly interesting given its location
at 5q 31–32 and its role as a tumor suppressor with its
anti-proliferative, anti adhesion, anti-angiogenic proper-
ties. The levels of activin -A increased 4 fold and analysis
of global gene expression revealed significant deregula-
tion of genes involved in extracellular matrix interactions,
erythropoiesis relative to healthy control.
Another recent study compared gene expression profile of
CD34 stem cells of 5q del MDS patients to healthy con-
trols and MDS patients with normal karyotype using
Affymetrix arrays. Approximately 40% of the probe sets
showing reduced expression levels localized to the del 5q
region. The commonly deleted region (CDR) region is
thought to comprise of approximately 40 genes that are
hypothesized to have a tumor suppressive role given the
observation that deletion of the 5q region leads to clonal
proliferation of myelodysplastic clone. Majority of the
genes associated with CDR showed lower expression but
several candidate genes (RBM22 and CSNK1A1, SPARC
and RPS14) associated with CDR of the 5 q syndrome
showed marked down regulation[40]. RBM22 is a highly
conserved ribosomal protein, and the effects of downreg-
ulation may include deregulated apoptosis by its action
on ALG-2(apoptosis linked gene). CSNK1A1 has recently
been shown to be important in Hedgehog signaling that
governs cell growth and a deregulation is observed in can-
cers. Downregulation of CSNK1A1 may contribute to
MDS by altering the Hh signaling. RPS14 is related to the
40S subunit of the ribosome that is downregulated in
Cd34 cells from MDS patients with del 5q[40]. RecentJournal of Hematology & Oncology 2009, 2:36 http://www.jhoonline.org/content/2/1/36
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work shows that downregulation of RPS14 leads to defec-
tive erythropoiesis and increased apoptosis in erythroid
progenitors [41].
Another candidate gene in the CDR region is Early growth
response gene (EGR-1), that encodes a transcription factor
involved in the regulation of cell proliferation and apop-
tosis[42]. The effect of lenalidomide treatment on expres-
sion of EGR-1 was studied in del 5q Burkitt's lymphoma
and del 5q multiple myeloma cell line. It was observed
that lenalidomide treatment did not influence the tran-
scriptional activity of EGR-1 gene, but increased the
nuclear export of EGR-1 in a dose dependent manner,
especially in those with a single copy of EGR-1 gene.
When the gene expression was blocked with an EGR1
siRNA, Burkitt's cells proliferated more than normal cells,
supporting the tumor suppressor role of EGR-1 in
Burkitt's cells. Thus, lenalidomide increases the nuclear
transport of the pro apoptotic and tumor suppressor EGR-
1, which could explain its cytotoxic effects on del 5q31
myelodysplastic clones.
In an effort to identify molecular markers of response to
lenalidomide, Ebert et al [43] collected bone marrow aspi-
rates of non 5 q del MDS patients before and after treat-
ment with lenalidomide and studied the difference in
gene expression between responders and non responders.
Differential expression of the genes that needed for eryth-
roid differentiation was noted in non responders than
responders. In patients who responded to lenalidomide,
they found that the bone marrow aspirates before treat-
ment showed decreased expression of the set of the genes
Mechanism of action of lenalidomide Figure 3
Mechanism of action of lenalidomide. Various mechanisms by which lenalidomide achieves clinical efficacy in hematologi-
cal malignancies.Journal of Hematology & Oncology 2009, 2:36 http://www.jhoonline.org/content/2/1/36
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needed for erythroid differentiation. The thinking is that
lenalidomide helps to overcome this differentiation block
and hence the clinical response is seen in that subset of
patients with decreased gene expression compared to the
non responders. This was thought have potential predict-
ability for benefit from lenalidomide therapy in non 5 q
del patients.
A recent study by Wei et al [44] demonstrates that the hap-
lodeficient enzymatic targets of lenalidomide within the
CDR are dual specificity phosphatases, Cdc25C and
PP2Acα. These phosphatases are coregulators of G2-M
checkpoint in the cell cycle and thus, their inhibition by
lenalidomide leads to G2 arrest and apoptosis. Since,
most MDS patients including those with deletion 5q
become refractory to Erythropoietin, the authors exam-
ined the molecular mechanisms by which lenalidomide
may modulate this effect. They observed that the CD45
phosphatase is overactivated in MDS and may inhibit Epo
receptor stimulated phosphorylation of stat5. Further-
more, they observed that lenalidomide is a Protein Tyro-
sine Phosphatase inhibitor of CD45 leading to reversal of
CD45 induced inhibition of EPO-R/STAT5 signaling
essential for hematopoiesis. The authors hypothesized
that lenalidomide may thus be able to restore sensitivity
to MDS by this mechanism. These concepts have led to
clinical trial effort using lenalidomide in combination
with erythropoietin in low grade MDS [45].
Conclusion
Lenalidomide has shown clinical efficacy in myelodyspla-
sia [46-50], multiple myeloma [51-56], chronic lym-
phocytic leukemia [9,57-59], primary systemic
amyloidosis [60,61], Non-Hodgkin's lymphoma [62],
solid tumors [63-70], myelofibrosis with myeloid meta-
plasia [71] and Waldenstrom Macroglobulinemia [72]. It
is also being increasedly used in combination with other
chemotherapeutic agents. In relapsed multiple myeloma,
it was combined with liposomal doxorubicin, vincristine
and dexamethasone[53] as well as with adriamycin and
dexamethasone[73]. Another combination being tested is
lenalidomide with melphalan and dexamethsaone in
treatment naïve myeloma[56]. A regimen combining
lenalidomide with docetaxel and carboplatin has been
tested in a phase 1 trial in advanced solid tumors[70].
Another very interesting combination is lenalidomide
and rituximab in diseases such as NHL[74], CLL[9] and
Waldenstrom Macroglobulinemia[72]. Preliminary
results from some of these trials appear encouraging and
final results are awaited. Even though various mecha-
nisms have been proposed to explain its efficacy, as a sin-
gle agent or in combination, in these conditions, the exact
molecular and cellular targets of lenalidomide are not
very well defined. It is possible that its efficacy is a result
of its effects on the immune system, angiogenesis and sig-
nal transduction or a combination of all of these. Figure 3
summarizes the mechanism of action of lenalidomide as
we know so far. Future studies will assess these mecha-
nisms as well as direct actions on the malignant cells.
These studies may uncover newer targets and lead to
efforts to enhance the efficacy of this interesting new
agent. These studies may also lead to development of
newer IMiDs that may target specific mechanisms of
action more potently, to further enhance their clinical
activity and may provide an important biologic rationale
to combine therapies with distinct, yet well defined site of
action.
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